WWWW.CVD | WWWW.CVD Web Site

WWWW.CVD Survey

The 4W for proper CVD management:
WHO · WHAT · WHEN · WHY

"(Required)" indicates required fields

Step 1 of 3 - Password

33%

ENTER THE PASS CODE TO START THE SURVEY(Required)

Dear Colleague,

On 26 June 2024, Alfasigma will organise a stand-alone event in Athens.
Prior to the wwww.CVD event, we would like to actively inter-ACT all together in the identification of met & unmet needs in CVD management.
In order to do so, we have thought about warming up our discussion during the event by submitting a survey whose results will facilitate a pro-active analysis of where we are and where we should go for the best vein-lymphatic advancement.

If you have agreed to participate, we kindly ask you to fill in the present survey by 9 June 2024.
A warm thank you for your time and effort for the best synergy in the wwww.CVD context.
We look forward to being all together on 26 June 2024.

Cristina Feijoo Cano, MD, PhD
Hospital Viamed Montecanal, Zaragoza (Spain)

Sergio Gianesini, MD PhD FACS
University of Ferrara (Italy)
Uniformed Services University of Health Sciences, Bethesda (USA)

Ana Negreanu, MD, PhD
CMDTAMP Bucharest and Carol Davila University, Bucharest (Romania)

Cristiana Vitale, MD, PhD
St George’s Hospital, London (UK)

The results will be collected in an anonymised and aggregated form.
In this regard, in compliance with the Personal Data Protection Regulation (GDPR), we invite you to read the privacy notice of Alfasigma.

I CONFIRM THAT I HAVE READ THE PRIVACY NOTICE(Required)

YES

Instructions for correct compilation:

You can interrupt the survey compilation at any time by pressing the 'SAVE AND CONTINUE LATER' button that you can find at the end of the survey.

To resume the compilation from where you left off, you will need to access the link provided in the email sent to the address you specified.

In case you cannot find the email in your inbox, we recommend checking the SPAM folder. For whatever need, do not hesitate to contact: wwww.cvd@infodyn.it

Please note that all questions are mandatory

Kindly report your professional profile

1. Year of specialisation:(Required)

Before 1973

Between 1974 and 1983

Between 1984 and 1993

Between 1994 and 2003

Between 2004 and 2013

After 2014

2. Specialty in:(Required)

Angiology

Vascular Medicine

Vascular surgery

General surgery

Internal Medicine

Geriatric Medicine

Dermatology

Radiology

Cardiology

Other

2. Specify other Specialty:(Required)

3. Country where you work:(Required)

Mexico

Poland

Portugal

Romania

Russia

Slovakia

Other

3. Specify other Country where you work:(Required)

4. As part of your clinical activity, do you perform one or more of the following treatment(s) for the management of chronic venous disease (CVD)?(Required)

Please select all those who apply

Stripping

Phlebectomy

ASVAL

CHIVA

EVLA

RFA

Sclerotherapy

MOCA

Glue

None

5. Among the previous answers of question 4, which one is the predominant one in your clinical practice, if any?(Required)

Stripping

Phlebectomy

ASVAL

CHIVA

EVLA

RFA

Sclerotherapy

MOCA

Glue

None

Considering your personal clinical experience in the management of patients with CVD

6. Please provide your description of “CVD patient”:(Required)

7. In which percentage of your patients CVD is associated with cardio-metabolic diseases?(Required)

Less than 1/3

Roughly half of them

More than 2/3

I am not sure about the percentage

8. In your experience, which of the following risk factors have the greatest potential to cause CVD?(Required)

Please select 3 from those listed below

Ageing

Familiarity

Foot venous pump insufficiency

Gender

Hormone therapy (Contraception, Hormone replacement therapy)

Number of pregnancies

Menopause

Obesity

Persistent exposition to warm temperature or latitude

Previous trauma at the level of the lower limbs

Physical inactivity

Type of dresses / shoes

Smoking

Unhealthy diet

Pelvic venous disorder

Hemorrhoidal disease

Constipation

Race

Sport type

Occupational exposure

Thyroid disfunction

Musculoskeletal disorders

Autoimmunity

9. In your experience, which of the following cardiovascular risk factors are more important in causing the progression of CVD?(Required)

Please select 3 from those listed below

Ageing

Familiarity

Foot venous pump insufficiency

Gender

Hormone therapy (Contraception, Hormone replacement therapy)

Number of pregnancies

Menopause

Obesity

Persistent exposition to warm temperature or latitude

Previous trauma at the level of the lower limbs

Physical inactivity

Type of dresses / shoes

Smoking

Unhealthy diet

Pelvic venous disorder

Hemorrhoidal disease

Constipation

Race

Sport type

Occupational exposure

Thyroid disfunction

Musculoskeletal disorders

Autoimmunity

10. Which of the following cardiovascular comorbidities are the most prevalent, in patients with CVD, who attend your clinic?(Required)

Please select 3 from those listed below

Abdominal aneurysms

CAD

Carotid atherosclerosis

Diabetes

Dyslipidaemia

Heart failure

Arterial Hypertension

Pulmonary hypertension

Lower Extremity Arterial Disease

Obesity

Post thrombotic Syndrome

11. Whenever you visit a patient with CVD, do you measure their blood pressure?(Required)

Never

Yes, sometimes

Yes, always

12. Do you take note of the CEAP classification of your patients with CVD?(Required)

Sometimes

Yes

13. Do you consider the CEAP classification as a disease severity score?(Required)

Yes

14. Which instrument do you usually use to assess the severity of CVD in the patients who attend your clinic?(Required)

More than one answer is admitted

Clinical judgement

CEAP classification

Ultrasound

Clinical questionnaire

14. Add the name the questionnaire/s you use in your clinical practice:(Required)

15. Whenever there is the indication to perform a non-conservative treatment, on the basis of what do you choose which treatment to perform among the ones available:(Required)

Please select 2 from those listed below

Personal experience

Type of treatment available in the facility / clinic where you should perform the treatment

Clinical features of the patient (i.e age, multimorbidity, etc)

Anatomical features

Hemodynamic features

Expected long term efficacy

Results of clinical trials

Patient’s preference

Cost effectiveness

Other

16. Do you prescribe venoactive medications to your patients with CVD?(Required)

Yes, always

Yes, but only in those patients who have clinical symptoms related to CVD

Yes, but only in those patients who don’t/cannot use elastocompression

Yes, but only in those patients who don’t/cannot be submitted to a non-conservative treatment

17. If you prescribe venous active drugs, how long do you prescribe them for:(Required)

Lifelong

6 months

More than 3 months

3 months

2 months

1 month

Until the resolution of the clinical scenario

Other

17. Specify how long do you prescribe them for:(Required)

18. Do you prescribe compression therapy to your patients with CVD?(Required)

Yes, always

Yes, but only in those patients who have clinical symptoms related to CVD

Yes, but only in those patients who don’t/cannot be submitted to a non-conservative treatment

19. If you prescribe compression therapy, how long do you prescribe it for?(Required)

Lifelong

6 months

More than 3 months

3 months

2 months

1 month

Until the clinical scenario is resolved

20. Why do you prescribe venoactive medications:(Required)

More than one answer is admitted

To reduce / improve clinical symptoms/signs attributable to CVD

To improve quality of life

To prevent / slow down the progression of CVD

To improve the results of a non-conservative treatment

Other

20. Specify(Required)

21. Do you consider venoactive medications an:(Required)

Alternative treatment to elastocompression

Alternative treatment to non-conservative treatment

Alternative treatment to elastocompression AND non-conservative treatment

Adjuvant treatment to elastocompression

Adjuvant treatment to non-conservative treatment

Adjuvant treatment to elastocompression AND non-conservative treatment

None of the above

22. Do you think that venoactive therapy can assist non-conservative treatment in order to obtain a:(Required)

More than one answer is admitted

Reduction of CVD progression

Improvement in clinical symptoms attributable to CVD

Quality of life improvement

Better short-term clinical results

Better long-term outcomes

Lower risk of post-intervention complications

Lower risk of recurrence after a non-conservative procedure

23. Do you think that venoactive therapy should be prescribed before a patient will be submitted to a non-conservative treatment?(Required)

Yes, always

Yes, only if patients have clinical symptoms/signs attributable to CVD

24. Do you think that venoactive therapy should be prescribed after a patient has undergone a non-conservative treatment?(Required)

It depends by the CEAP class after the procedure

Yes, always

Other

24. Specify(Required)

25. Based on what, do you choose among the available venoactive medications?(Required)

Personal experience

Results of clinical trials

Dispensability from the National Health Service

Patient preference

Other

25. Specify(Required)

26. Do you prescribe nutraceutical products to your patients with CVD?(Required)

Yes

27. Do your patients with CVD ask you about nutraceutical products?:(Required)

Yes

28. As a prescribing physician, do you have any barrier to long-term prescription of venoactive therapy?(Required)

More than one answer is admitted

YES, due to the cost of therapy incurred by the patient

YES, in patients already receiving a significant amount of drugs

YES, in those patients who did not have short-term clinical benefits.

YES, due to the lack of data supporting a positive long-term cost-benefit ratio

Other

28. Define other barriers(Required)

29. What do you consider effective in preventing CVD progression among the following options:(Required)

More than one answer is admitted

Healthy lifestyle

Elastocompression

Venoactive medications

Nutraceutical products

Non conservative treatment

30. Considering all the treatments available for the management of CVD, which is the most important goal that you want to achieve when you treat your patients?(Required)

To satisfy patient requests

To reduce / improve clinical symptoms

To improve quality of life

To prevent the progression of CVD

Other

30. Specify(Required)

31. Thinking at your patients with CVD, how do you score their compliance to:

31.a Lifestyle changes(Required)

31.b Compression therapy(Required)

31.c Medical therapy(Required)